fbpx
March 28, 2023

No Added Benefit of Time-Restricted Eating in NAFLD No Added Benefit of Time-Restricted Eating in NAFLD

Adding time-restricted eating to a calorie-restricted diet did not provide added benefits in adults with obesity and nonalcoholic fatty liver disease (NAFLD), according to the results […]
March 28, 2023

Safety, Efficacy of Analgesics for Low Back Pain ‘Uncertain’ Safety, Efficacy of Analgesics for Low Back Pain ‘Uncertain’

Despite decades of research, there’s still considerable uncertainty about the comparative effectiveness and safety of analgesics for the treatment of acute low back pain, new research […]
March 27, 2023

Topical Delgocitinib Effective for Hand Eczema in Phase 3 Trial Topical Delgocitinib Effective for Hand Eczema in Phase 3 Trial

NEW ORLEANS — Adults with moderate to severe chronic hand eczema who were randomized to treatment with delgocitinib cream had significantly greater improvement in efficacy outcomes at 16 […]
March 27, 2023

Hydroxyurea Underused in Youth With Sickle Cell Anemia Hydroxyurea Underused in Youth With Sickle Cell Anemia

Even after endorsement in updated guidelines, hydroxyurea is substantially underused in youth with sickle cell anemia (SCA), new research indicates. SCA can lead to pain crises, […]
March 27, 2023

Who Is Most Likely to Get Long COVID? Patient Data May Tell Who Is Most Likely to Get Long COVID? Patient Data May Tell

Editor’s note: Find the latest long COVID news and guidance in Medscape’s Long COVID Resource Center. Good news and bad news on the long COVID front: […]
March 27, 2023

Air Pollution May Be Causing Your Eczema Air Pollution May Be Causing Your Eczema

New research shows that chemicals from car exhaust, wildfires, and cigarette smoke impair our skin’s ability to make healthy oil, making it more likely to get […]
March 27, 2023

Anifrolumab Shows Promise in Refractory Discoid Lupus Anifrolumab Shows Promise in Refractory Discoid Lupus

Anifrolumab appears to improve outcomes in patients with refractory discoid lupus erythematosus (DLE), especially in those with severe or recalcitrant disease, a small retrospective study reports. DLE, […]
March 27, 2023

FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar

The US Food and Drug Administration has approved a citrate-free, 100 mg/mL formulation of the biosimilar adalimumab-adaz (Hyrimoz), according to a statement from manufacturer Sandoz. Hyrimoz, […]
March 27, 2023

Antibiotics May Not Help Survival of Patients Hospitalized With Viral Infections Antibiotics May Not Help Survival of Patients Hospitalized With Viral Infections

LONDON (Reuters) – Most patients admitted to hospitals with acute viral infections are given antibiotics as a precaution against bacterial co-infection, but this practice may not […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795796797798799800801802803804805806807
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0